Clinical Trial Finder

Inclusion Criteria:

• - Sarcomas of soft tissues or viscera ; - Inoperable metastatic or locally advanced disease ; - Indication for 2nd-line treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine after failure of 1st-line anthracycline therapy ; - Patient covered by French social security ; - Written, signed, informed consent ;

  Exclusion Criteria:

  - Poor understanding of French ; - Difficulty accessing a computer ; - Pregnant or nursing woman ; - Person deprived of liberty or under guardianship ; - Impossibility of undergoing medical follow-up for geographical, social or psychological reasons.

ePPS-2202 is a phase 3, randomised,open-label, controlled, multicentre interventional study, designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP in patients with metastatic of locally advanced sarcomas with indication of a second-line treatment with pazopanib, tracbectedine, eribuline, ifosfamide or dacarbazine after failure of a first-line anthracycline-based regimen. Participants will be randomised to the experimental arm or the control arm. Patients in the experimental arm will receive the dematerialised PCP in addition to the standard PCP while patients in the control arm will receive the standard PCP alone. All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up. The main analysis will compare the proportion of patients in each arm who experience at least one severe adverse event during the first 3 months of second-line treatment. Adverse events will be considered severe if they are graded 3 or higher according to NCI-CTCAE v5.0.

Arms

Interventions